Cochrane Abstracts
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone���sensitive_prostate_cancer_Edited__no_change_to_conclusions_. Accessed 29 September 2023.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone���sensitive_prostate_cancer_Edited__no_change_to_conclusions_. Accessed September 29, 2023.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone���sensitive_prostate_cancer_Edited__no_change_to_conclusions_
Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer [Internet]. In: Cochrane Abstracts. [cited 2023 September 29]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone���sensitive_prostate_cancer_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
ID - 431195
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone���sensitive_prostate_cancer_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -
